Vitamin D Supplementation in Veterans With Early-Stage Prostate Cancer
Status:
Completed
Trial end date:
2014-10-30
Target enrollment:
Participant gender:
Summary
Vitamin D promotes the differentiation of prostate cancer cells, maintains the differentiated
phenotype of prostate epithelial cells, and can induce prostate cancer cell death, raising
the possibility that vitamin D deficiency over time promotes the progression of subclinical
prostate cancer to clinical disease. The investigators propose to conduct a clinical study
aimed at measuring the efficacy of vitamin D3 (4000IU/day) supplementation in Veterans
diagnosed with low-risk, early-stage prostate cancer, who elect to have their disease
monitored through active surveillance. The successful completion of this proposed clinical
study will allow us to determine whether correcting vitamin D deficiency in Veterans
diagnosed with early-stage prostate cancer will prevent progression of their disease and
improve their prognosis.
Phase:
Phase 2
Details
Lead Sponsor:
VA Office of Research and Development
Collaborator:
Medical University of South Carolina
Treatments:
Cholecalciferol Ergocalciferols Vitamin D Vitamins